Trials / Completed
CompletedNCT02801669
Study of DU-176b Aged 80 Years or Older
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study of DU-176b in Patients With NVAF Aged 80 Years or Older Who Are Ineligible for Available Oral Anticoagulation Therapy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 984 (actual)
- Sponsor
- Daiichi Sankyo Co., Ltd. · Industry
- Sex
- All
- Age
- 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of edoxaban in patients with non-valvular NVAF aged 80 years or older who are ineligible for available oral anticoagulation therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Du-176b | DU-176b orally administered at a dose of 15 mg once daily. |
| DRUG | placebo | Placebo orally administered once daily. |
Timeline
- Start date
- 2016-08-05
- Primary completion
- 2019-12-27
- Completion
- 2019-12-27
- First posted
- 2016-06-16
- Last updated
- 2020-11-19
- Results posted
- 2020-11-19
Locations
164 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT02801669. Inclusion in this directory is not an endorsement.